Skip to main content



Inflammatory Arthritis and Hidradenitis Suppurativa

Dec 09, 2022

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or 

Read Article

ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth

Dec 08, 2022

As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R. 8800), and telehealth protections in

Read Article
cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Dec 07, 2022

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The BE COMPLETE study was a phase

Read Article

The Top 10 Research Priorities in Psoriatic Arthritis

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article
cardiac2.jpg (keep)

TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis

Dec 05, 2022

A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).

Read Article

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article


Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Nov 28, 2022

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.

The results of this phase II trial were recently presented at ACR 2022. This  phase II multinational trial enrolled 363 adults with

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

The meeting itself was very

Read Article
RA, hands, MCP, deformity

New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis

Nov 10, 2022

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.

Devised, reviewed and updated by an

Read Article

Update: axSpA Recommendations

Nov 09, 2022

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016. The current update

Read Article

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections

Nov 07, 2022

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Read Article
RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Nov 04, 2022

Dr. Jack Cush reviews the news and journal articles from this past week on  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

  1. Population study shows among vaccinated gout pts, COVID breakthrough

Read Article

SLE T2T - Lupus Low Disease Activity State Predicts Outcomes

Nov 03, 2022

Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.

Read Article

2022 CDC Clinical Practice Guideline on Opioid Prescribing

Nov 03, 2022

The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.

This guideline provides recommendations for clinicians

Read Article

Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?

Nov 02, 2022

Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA). Now an open label study of ixekizumab (IXE) treated axSpA patients in remission has shown that the vast majority of IXE withdrawal patients who later flared were able to recapture

Read Article
warning, caution

EMA Crack Down on JAK Inhibitors

Oct 31, 2022

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Read Article
RheumNow Podcast square

Infections & Lupus (10.28.2022)

Oct 28, 2022

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article

Growing Confidence in Biosimilars?

Oct 27, 2022

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

Read Article

Update to Axial Spondyloarthritis Guidance

MedPage Today
Oct 26, 2022

EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.

The revision included 15 recommendations in total. Of these, 11 either remained the same from earlier editions or involved minor wording

Read Article

New ACR/EULAR Guideline Expands RA Remission Definition

MedPage Today
Oct 26, 2022

Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.

The more relaxed criteria from the American College of Rheumatology (ACR) and the

Read Article

2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis

Oct 24, 2022

Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).

Read Article